Published in Curr Alzheimer Res on November 01, 2004
How citation distortions create unfounded authority: analysis of a citation network. BMJ (2009) 3.66
A dynamic relationship between intracellular and extracellular pools of Abeta. Am J Pathol (2006) 1.66
Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease. Proc Natl Acad Sci U S A (2005) 1.51
Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol (2009) 1.44
Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. J Biol Chem (2010) 1.22
Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. J Neural Transm (Vienna) (2009) 1.22
Activation of the amyloid cascade in apolipoprotein E4 transgenic mice induces lysosomal activation and neurodegeneration resulting in marked cognitive deficits. J Neurosci (2008) 1.11
Mechanisms underlying basal and learning-related intrinsic excitability in a mouse model of Alzheimer's disease. Neurobiol Aging (2009) 1.06
Targets for AD treatment: conflicting messages from γ-secretase inhibitors. J Neurochem (2011) 1.05
Neuronal or glial expression of human apolipoprotein e4 affects parenchymal and vascular amyloid pathology differentially in different brain regions of double- and triple-transgenic mice. Am J Pathol (2006) 0.94
Genetically augmenting Abeta42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice. Am J Pathol (2006) 0.93
Independent effects of intra- and extracellular Abeta on learning-related gene expression. Am J Pathol (2009) 0.87
APP-BP1 inhibits Abeta42 levels by interacting with Presenilin-1. Mol Neurodegener (2007) 0.87
HH domain of Alzheimer's disease Abeta provides structural basis for neuronal binding in PC12 and mouse cortical/hippocampal neurons. PLoS One (2010) 0.85
Advances on the understanding of the origins of synaptic pathology in AD. Curr Genomics (2007) 0.83
PuF, an antimetastatic and developmental signaling protein, interacts with the Alzheimer's amyloid-β precursor protein via a tissue-specific proximal regulatory element (PRE). BMC Genomics (2013) 0.82
Amino acids variations in amyloid-beta peptides, mitochondrial dysfunction, and new therapies for Alzheimer's disease. J Bioenerg Biomembr (2009) 0.79
The protein oxidation repair enzyme methionine sulfoxide reductase a modulates Aβ aggregation and toxicity in vivo. Antioxid Redox Signal (2015) 0.75
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03
Alzheimer's disease. N Engl J Med (2010) 13.13
Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron (2005) 6.20
Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron (2004) 5.52
Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging (2003) 3.83
Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci (2005) 3.18
Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci U S A (2009) 2.96
Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest (2004) 2.80
Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nat Neurosci (2010) 2.79
Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem (2005) 2.56
Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. J Neurosci (2006) 2.45
Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem (2006) 2.33
IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J Cell Biol (2009) 2.16
Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci (2010) 2.12
M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron (2006) 2.07
Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. J Neurosci (2007) 2.00
A physiologic signaling role for the gamma -secretase-derived intracellular fragment of APP. Proc Natl Acad Sci U S A (2002) 1.97
Dysregulated IP3 signaling in cortical neurons of knock-in mice expressing an Alzheimer's-linked mutation in presenilin1 results in exaggerated Ca2+ signals and altered membrane excitability. J Neurosci (2004) 1.92
Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J Neurosci (2008) 1.88
SERCA pump activity is physiologically regulated by presenilin and regulates amyloid beta production. J Cell Biol (2008) 1.84
Linking calcium to Abeta and Alzheimer's disease. Neuron (2008) 1.82
Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3beta. Ann Neurol (2008) 1.71
Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol Aging (2005) 1.68
A dynamic relationship between intracellular and extracellular pools of Abeta. Am J Pathol (2006) 1.66
Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J Immunol (2009) 1.66
Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J Neuroinflammation (2005) 1.64
Impaired adult neurogenesis in the dentate gyrus of a triple transgenic mouse model of Alzheimer's disease. PLoS One (2008) 1.62
Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis (2009) 1.60
Calpain inhibitor A-705253 mitigates Alzheimer's disease-like pathology and cognitive decline in aged 3xTgAD mice. Am J Pathol (2012) 1.60
Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol Aging (2007) 1.58
Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res (2008) 1.56
Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. Am J Pathol (2008) 1.55
Enhanced caffeine-induced Ca2+ release in the 3xTg-AD mouse model of Alzheimer's disease. J Neurochem (2005) 1.52
Calcium dysregulation in Alzheimer's disease: recent advances gained from genetically modified animals. Cell Calcium (2005) 1.52
Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res (2008) 1.51
Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease. Proc Natl Acad Sci U S A (2005) 1.51
Caspase-3 dependent proteolytic activation of protein kinase C delta mediates and regulates 1-methyl-4-phenylpyridinium (MPP+)-induced apoptotic cell death in dopaminergic cells: relevance to oxidative stress in dopaminergic degeneration. Eur J Neurosci (2003) 1.49
Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathology. J Neurosci (2008) 1.49
Caspase-3-dependent proteolytic cleavage of protein kinase Cdelta is essential for oxidative stress-mediated dopaminergic cell death after exposure to methylcyclopentadienyl manganese tricarbonyl. J Neurosci (2002) 1.47
Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J Neurosci (2007) 1.47
Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-β accumulation and independently accelerates the development of tau abnormalities. J Neurosci (2011) 1.47
Neural stem cells improve memory in an inducible mouse model of neuronal loss. J Neurosci (2007) 1.46
Protein kinase Cdelta is a key downstream mediator of manganese-induced apoptosis in dopaminergic neuronal cells. J Pharmacol Exp Ther (2004) 1.44
Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal β-catenin pathway function in an Alzheimer's disease model. J Immunol (2011) 1.36
Relevance of transgenic mouse models to human Alzheimer disease. J Biol Chem (2008) 1.36
VCP associated inclusion body myopathy and paget disease of bone knock-in mouse model exhibits tissue pathology typical of human disease. PLoS One (2010) 1.34
Sustained interleukin-1β overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model. J Neurosci (2013) 1.32
Age-dependent sexual dimorphism in cognition and stress response in the 3xTg-AD mice. Neurobiol Dis (2007) 1.30
Dieldrin-induced neurotoxicity: relevance to Parkinson's disease pathogenesis. Neurotoxicology (2005) 1.30
Enhanced neuronal excitability in the absence of neurodegeneration induces cerebellar ataxia. J Clin Invest (2004) 1.29
Mifepristone alters amyloid precursor protein processing to preclude amyloid beta and also reduces tau pathology. Biol Psychiatry (2013) 1.28
Intraneuronal beta-amyloid accumulation in the amygdala enhances fear and anxiety in Alzheimer's disease transgenic mice. Biol Psychiatry (2009) 1.25
Role of proteolytic activation of protein kinase Cdelta in oxidative stress-induced apoptosis. Antioxid Redox Signal (2003) 1.24
Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci (2007) 1.24
ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Proc Natl Acad Sci U S A (2010) 1.23
Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice. J Neurochem (2007) 1.22
Learning decreases A beta*56 and tau pathology and ameliorates behavioral decline in 3xTg-AD mice. J Neurosci (2007) 1.22
Androgens regulate the development of neuropathology in a triple transgenic mouse model of Alzheimer's disease. J Neurosci (2006) 1.21
Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am J Pathol (2007) 1.21
Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am J Pathol (2009) 1.19
Presenilin is necessary for efficient proteolysis through the autophagy-lysosome system in a γ-secretase-independent manner. J Neurosci (2011) 1.18
Multiple events lead to dendritic spine loss in triple transgenic Alzheimer's disease mice. PLoS One (2010) 1.17
Ca2+ signaling in mouse cortical neurons studied by two-photon imaging and photoreleased inositol triphosphate. J Neurosci (2003) 1.17
The role of nicotinic acetylcholine receptors in Alzheimer's disease. J Physiol Paris (2006) 1.11
Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. Proc Natl Acad Sci U S A (2002) 1.11
Two distinct mechanisms for actin capping protein regulation--steric and allosteric inhibition. PLoS Biol (2010) 1.09
Peripherally expressed neprilysin reduces brain amyloid burden: a novel approach for treating Alzheimer's disease. J Neurosci Res (2009) 1.08
Inflammation induced by infection potentiates tau pathological features in transgenic mice. Am J Pathol (2011) 1.07
Soluble aβ promotes wild-type tau pathology in vivo. J Neurosci (2012) 1.06
Pharmacologic reversal of neurogenic and neuroplastic abnormalities and cognitive impairments without affecting Aβ and tau pathologies in 3xTg-AD mice. Acta Neuropathol (2010) 1.05
Neural stem cells genetically-modified to express neprilysin reduce pathology in Alzheimer transgenic models. Stem Cell Res Ther (2014) 1.05
Spatial frequency domain imaging of intrinsic optical property contrast in a mouse model of Alzheimer's disease. Ann Biomed Eng (2011) 1.05
Microglia as a potential bridge between the amyloid beta-peptide and tau. Ann N Y Acad Sci (2004) 1.03
Age-related accumulation of Reelin in amyloid-like deposits. Neurobiol Aging (2007) 1.02
Soluble amyloid precursor protein induces rapid neural differentiation of human embryonic stem cells. J Biol Chem (2011) 1.01
Astrocytes: conductors of the Alzheimer disease neuroinflammatory symphony. Exp Neurol (2012) 1.01
Regional cerebral glucose uptake in the 3xTG model of Alzheimer's disease highlights common regional vulnerability across AD mouse models. Brain Res (2010) 1.00
Reductions in amyloid-beta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation. J Alzheimers Dis (2010) 1.00
Pathogenic accumulation of APP in fast twitch muscle of IBM patients and a transgenic model. Neurobiol Aging (2005) 0.99
Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation. Ann Neurol (2011) 0.97
Presenilin regulates capacitative calcium entry dependently and independently of gamma-secretase activity. Biochem Biophys Res Commun (2004) 0.97
Genetically altering Abeta distribution from the brain to the vasculature ameliorates tau pathology. Brain Pathol (2008) 0.96
Environmental neurotoxin dieldrin induces apoptosis via caspase-3-dependent proteolytic activation of protein kinase C delta (PKCdelta): Implications for neurodegeneration in Parkinson's disease. Mol Brain (2008) 0.95
Amyloid-β protein impairs Ca2+ release and contractility in skeletal muscle. Neurobiol Aging (2008) 0.94
Genetically augmenting Abeta42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice. Am J Pathol (2006) 0.93
M1 agonists as a potential disease-modifying therapy for Alzheimer's disease. Curr Alzheimer Res (2009) 0.93
Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline. Am J Pathol (2011) 0.93
Aspirin-triggered lipoxin A4 stimulates alternative activation of microglia and reduces Alzheimer disease-like pathology in mice. Am J Pathol (2013) 0.93
Formulation of a medical food cocktail for Alzheimer's disease: beneficial effects on cognition and neuropathology in a mouse model of the disease. PLoS One (2010) 0.93
Activation of cell cycle proteins in transgenic mice in response to neuronal loss but not amyloid-beta and tau pathology. J Alzheimers Dis (2009) 0.92